The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N05 | Psycholeptics | |
| 3 | N05A | Antipsychotics | |
| 4 | N05AX | Other antipsychotics | |
| 5 | N05AX15 |
| Active Ingredient | Description | |
|---|---|---|
| Cariprazine |
Cariprazine is indicated for the treatment of schizophrenia in adult patients. The mechanism of action of cariprazine is not fully known. However the therapeutic effect of cariprazine may be mediated through a combination of partial agonist activity at dopamine D3, D2 (Ki values of 0.085-0.3 nM versus 0.49-0.71 nM respectively) and serotonin 5-HT1A receptors (Ki values of 1.4-2.6 nM), and antagonist activity at serotonin 5-HT2B, 5-HT2A and histamine H1 receptors (Ki values of 0.58-1.1 nM, 18.8 nM and 23.3 nM, respectively). |
| Title | Information Source | Document Type | |
|---|---|---|---|
| REAGILA Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC | |
| SYMVENU Hard capsule | Health Sciences Authority (SG) | MPI, Generic |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
